Regulatory T cell therapy for Graft-versus-Host Disease

Memnon Lysandrou; Dionysia Kefala; Janaki Manoja Vinnakota; Nikolaos Savvopoulos; Robert Zeiser; Alexandros Spyridonidis

doi:10.1038/s41409-025-02553-x

Regulatory T cell therapy for Graft-versus-Host Disease

Bone Marrow Transplant. 2025 Apr 16. doi: 10.1038/s41409-025-02553-x. Online ahead of print.

Authors

Memnon Lysandrou^{1

2}, Dionysia Kefala¹, Janaki Manoja Vinnakota², Nikolaos Savvopoulos¹, Robert Zeiser², Alexandros Spyridonidis³

Affiliations

¹ Bone Marrow Transplantation Unit and Institute of Cell Therapy, University of Patras, Patras, Greece.
² Department of Medicine I, Medical Center University of Freiburg, Faculty of Medicine, Albert Ludwigs University Freiburg, Freiburg, Germany.
³ Bone Marrow Transplantation Unit and Institute of Cell Therapy, University of Patras, Patras, Greece. spyridonidis@upatras.gr.

PMID: 40240498
DOI: 10.1038/s41409-025-02553-x

Abstract

Graft-versus-Host Disease (GvHD) is the main cause of morbidity and mortality of allogeneic hematopoietic cell transplantation (allo-HCT). Conventional immunosuppressive pharmacotherapy remains the backbone of GvHD prevention and treatment with suboptimal outcomes especially for patients with refractory disease. Adoptive immunotherapy with regulatory T-cells (Treg) stands as an alternative approach that aims to restore immune tolerance and circumvent prolonged immunosuppression albeit preserving the beneficial Graft-versus-Leukaemia (GvL) effect. In this review, we summarise recent knowledge on Treg biology, clinical applications of various Tregs subtypes in the setting of GvHD and future endeavours of the field.

Publication types

Review

Abstract

Publication types

Grants and funding